Trial Profile
A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Assess Comparability of a Single Phase 3 Lot and a Single Commercial Lot of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Healthy Adult Smokers.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Nicotine abuse vaccine (Primary)
- Indications Drug dependence; Smoking withdrawal
- Focus Pharmacodynamics; Registrational
- Sponsors Nabi Biopharmaceuticals
- 11 May 2012 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.
- 11 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.